Immunophenotyping of peripheral blood in NSCLC patients discriminates responders to immune checkpoint inhibitors
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Immunophenotyping of peripheral blood in NSCLC patients discriminates responders to immune checkpoint inhibitors ; volume:150 ; number:2 ; day:21 ; month:2 ; year:2024 ; pages:1-13 ; date:2.2024
Journal of cancer research and clinical oncology ; 150, Heft 2 (21.2.2024), 1-13, 2.2024
- Urheber
-
Krizova, Ludmila
Benesova, Iva
Zemanova, Petra
Spacek, Jan
Strizova, Zuzana
Humlova, Zuzana
Mikulova, Veronika
Petruzelka, Lubos
Vocka, Michal
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s00432-024-05628-2
- URN
-
urn:nbn:de:101:1-2405232119365.904925956978
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:56 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Krizova, Ludmila
- Benesova, Iva
- Zemanova, Petra
- Spacek, Jan
- Strizova, Zuzana
- Humlova, Zuzana
- Mikulova, Veronika
- Petruzelka, Lubos
- Vocka, Michal
- SpringerLink (Online service)
Ähnliche Objekte (12)
Adjuvant and neoadjuvant use of immune checkpoint inhibitors in NSCLC
Identification of responders to immune checkpoint therapy : which biomarkers have the highest value?
Immune Checkpoint Inhibitors and Radiotherapy in NSCLC Patients: Not Just a Fluke
Peripheral nervous system adverse events associated with immune checkpoint inhibitors
Induction immune-checkpoint inhibitors for resectable oncogene-mutant NSCLC: A multicenter pooled analysis
Immune checkpoint inhibitors alone vs immune checkpoint inhibitors—combined chemotherapy for NSCLC patients with high PD-L1 expression: a network meta-analysis
Immune checkpoint inhibitors in MITF family translocation renal cell carcinomas and genetic correlates of exceptional responders
Risk factors of immune checkpoint inhibitor-related pneumonitis after neoadjuvant immunochemotherapy for resectable NSCLC
Prediction of patients’ response to immune checkpoint inhibitors in the treatment of advanced NSCLC
Reconstitution of peripheral blood T cell receptor β immune repertoire in immune checkpoint inhibitors associated myocarditis
Influenza Virus Infects and Depletes Activated Adaptive Immune Responders
Neoadjuvant immune checkpoint inhibitor reduced recurrence in operable NSCLC patients with pathological complete response: a retrospective analysis
Adjuvant and neoadjuvant use of immune checkpoint inhibitors in NSCLC
Identification of responders to immune checkpoint therapy : which biomarkers have the highest value?
Immune Checkpoint Inhibitors and Radiotherapy in NSCLC Patients: Not Just a Fluke
Peripheral nervous system adverse events associated with immune checkpoint inhibitors
Induction immune-checkpoint inhibitors for resectable oncogene-mutant NSCLC: A multicenter pooled analysis
Immune checkpoint inhibitors alone vs immune checkpoint inhibitors—combined chemotherapy for NSCLC patients with high PD-L1 expression: a network meta-analysis
Immune checkpoint inhibitors in MITF family translocation renal cell carcinomas and genetic correlates of exceptional responders
Risk factors of immune checkpoint inhibitor-related pneumonitis after neoadjuvant immunochemotherapy for resectable NSCLC
Prediction of patients’ response to immune checkpoint inhibitors in the treatment of advanced NSCLC
Reconstitution of peripheral blood T cell receptor β immune repertoire in immune checkpoint inhibitors associated myocarditis
Influenza Virus Infects and Depletes Activated Adaptive Immune Responders
Neoadjuvant immune checkpoint inhibitor reduced recurrence in operable NSCLC patients with pathological complete response: a retrospective analysis
Adjuvant and neoadjuvant use of immune checkpoint inhibitors in NSCLC
Identification of responders to immune checkpoint therapy : which biomarkers have the highest value?
Immune Checkpoint Inhibitors and Radiotherapy in NSCLC Patients: Not Just a Fluke
Peripheral nervous system adverse events associated with immune checkpoint inhibitors
Induction immune-checkpoint inhibitors for resectable oncogene-mutant NSCLC: A multicenter pooled analysis
Immune checkpoint inhibitors alone vs immune checkpoint inhibitors—combined chemotherapy for NSCLC patients with high PD-L1 expression: a network meta-analysis
Immune checkpoint inhibitors in MITF family translocation renal cell carcinomas and genetic correlates of exceptional responders
Risk factors of immune checkpoint inhibitor-related pneumonitis after neoadjuvant immunochemotherapy for resectable NSCLC
Prediction of patients’ response to immune checkpoint inhibitors in the treatment of advanced NSCLC
Reconstitution of peripheral blood T cell receptor β immune repertoire in immune checkpoint inhibitors associated myocarditis
Influenza Virus Infects and Depletes Activated Adaptive Immune Responders